Beam Therapeutics (BEAM) is back in focus after the FDA cleared its investigational new drug application for BEAM-304, allowing a Phase 1/2 trial in phenylketonuria patients to move ahead.

Those BEAM-304 headlines arrive after a strong run, with Beam Therapeutics posting a 35.8% 90 day share price return and a 68.4% 1 year total shareholder return. This comes even though the share price is around $33.48 after a recent single day pullback.

If this kind of genetic medicine story interests you, it could be worth widening the lens and checking out other healthcare companies applying AI in their pipelines through our 39 healthcare AI stocks

With Beam Therapeutics now cleared to start human testing of BEAM-304 and the stock up strongly over the past year, investors are weighing the next move: is Beam undervalued here, or is future growth already priced in?

Most Popular Narrative: 77.7% Undervalued

The most followed narrative on Beam Therapeutics pegs fair value at $150 per share, well above the recent $33.48 close, and anchors that view in its base editing platform.

The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool. By creating double-strand DNA breaks, they introduce significant risks, including unpredictable insertions, deletions, and large genomic rearrangements. Beam represents "Gene Editing 2.0." Its base editing platform is a "molecular pencil," a precision instrument that chemically rewrites a single "letter" of the genetic code without cutting the DNA backbone. This approach offers a potentially superior safety and precision profile, designed to mitigate the core risks that plague its predecessors.

Want to see why this narrative argues Beam Therapeutics could justify a much higher price? The rNPV hinges on a handful of high impact programs, aggressive revenue assumptions and a margin profile more often associated with established leaders. The full write up shows exactly how those moving parts combine to reach that $150 fair value.

Result: Fair Value of $150 (UNDERVALUED)

However, this bullish Beam Therapeutics narrative could be knocked off course if key trials disappoint on safety or efficacy, or if regulatory reviews prove slower than hoped.

Another View: What Beam Therapeutics' Sales Multiple Is Saying

While that user narrative points to a $150 fair value for Beam Therapeutics, the stock tells a different story when you look at sales. BEAM trades on a P/S of 20.3x, compared with 12.4x for the US biotech industry, 15.9x for peers, and a fair ratio of 1.3x that our model suggests the market could eventually move toward.

In plain terms, the current price already assumes far stronger outcomes than the broader group. This raises the risk that any disappointment in trials or timing could hit sentiment hard. The key question for you is whether Beam’s pipeline justifies paying such a steep premium today.

Next Steps

With all this in mind, are you leaning bullish or cautious on Beam Therapeutics, and how quickly do you want to firm up that view? To weigh the upside potential against the concerns in detail, start by reviewing the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Beam Therapeutics?

If Beam Therapeutics has sharpened your interest in high conviction opportunities, do not stop here. Broaden your watchlist with focused idea lists built from the Simply Wall St screener.

• Target potential mispricing by reviewing companies that look cheap relative to their fundamentals through our 41 high quality undervalued stocks.
• Strengthen the defensive side of your portfolio by scanning for businesses with strong financial footing and dependable metrics using the solid balance sheet and fundamentals stocks screener (47 results).
• Aim ahead of the crowd by tracking under the radar companies with solid fundamentals via our screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.